High-density postbiotic formulations are gaining traction as brands look for more stable, high-impact microbiome solutions.
Growing scientific and commercial interest has brought increased attention to postbiotics, defined as preparations of inactivated microbial cells that confer health benefits to the human host.
The non-viable nature of postbiotics offers enhanced stability and formulation flexibility, enabling higher-dose applications without concerns related to microbial viability. In addition, postbiotics may be co-administered alongside conventional probiotic products without the risk of functional interference, supporting broader integration into existing microbiome regimens.
Because postbiotics consist of non-viable microbial cells, they are generally associated with:
- Enhanced heat and pH stability
- No cold-chain requirement
- High-dose flexibility
- Compatibility with existing probiotic regimens
These characteristics have contributed to expanding interest in postbiotics across functional foods, dietary supplements, and on-the-go delivery formats.
Growing scientific interest in microbial-cell-mediated mechanisms
While probiotics act through colonization and metabolic activity, postbiotics rely on the bioactivity of structural components – such as cell-wall fragments, EPS, peptidoglycans, and intracellular metabolites – to interact with the host.
Recent studies have explored how these inactivated microbial cells may influence:
- Immune modulation, including cytokine signaling pathways
- Gut barrier integrity, helping regulate intestinal permeability
- Microbiome communication, potentially shifting microbial balance
- Gut comfort and stress response, via interactions with epithelial and immune cells
This mechanism has opened opportunities for high-density formulations, where large quantities of microbial cells are delivered without viability constraints – an approach increasingly adopted in Asia Pacific and gaining traction globally.
High-density postbiotic formulations as an emerging strategy
Because the microbial cell itself functions as the active agent, some formulators are exploring higher-cell-count postbiotic designs to amplify physiological interactions. This strategy supports products aimed at gut comfort, immune health, and overall microbiome balance, especially for consumers seeking rapid or noticeable effects.
Korea, in particular, has become a leading testing ground for these formulations due to strong consumer familiarity with fermented foods and a highly developed supplement market. In Korea, pharmacies and supplement-focused channels are seeing a rise in high-density postbiotic products – introduced as a way to offer consumers fast, intuitive benefits and to strengthen repeat purchase behavior.
In parallel, formulations that pair high-density postbiotics with probiotic and prebiotic ingredients are increasingly appearing, reflecting an evolving trend toward more integrated multi-biotic solutions.
Example of high-density application
As one example of this approach, Atomy has introduced a new high-density postbiotic supplement, Atomy Postbiotics Core Balance 5000, delivering 500 billion postbiotic cells per serving. This positions the product among the higher dose postbiotic formulations currently emerging in the market.
With the strong international performance of Atomy Probiotics 10+, one of the company’s most consistently top-selling products, and Atomy SCI Microbiome as a foundation, the new postbiotic entry is expected to further reinforce Atomy’s expanding microbiome-focused product portfolio across its global direct-to-consumer network.
The formulation combines seven types of postbiotics alongside complementary ingredients such as fermented dietary fiber (Synbio-glucan) and Oniro (arginyl-fructose) and is presented in a fast-dissolving slow-melting format designed for convenient intake. Central to the formulation is a high-density heat-inactivated Lactobacillus plantarum component (beLP1), contributing to the product’s concentrated postbiotic profile.
Proprietary postbiotic technology
beLP1 is a clinically researched heat-inactivated Lactobacillus plantarum strain developed by Bereum. The strain originates from kimchi, Korea’s traditional fermented food recognized globally as a ‘superfood’ rich in beneficial bacteria, and is plant-associated, making it naturally compatible with vegan and plant-based formulations.
Bereum, a Korean postbiotics specialist with decades of research experience in non-viable microbial solutions, has developed proprietary capabilities in the following:
- High-density microbial cultivation
- Precision heat-inactivation technology
- Strain selection based on functional bioactivity
These technologies enable the production of stable, concentrated microbial cells while preserving structurally active components following inactivation. In particular, the company focuses on identifying strains that retain functional efficacy in their inactivated state. For beLP1, the specification reaches up to 3 trillion cells per gram, enabling high functional delivery at comparatively low inclusion levels.
Atomy selected Bereum as its postbiotics development partner, and the two companies have collaborated over the past three years to co-develop a next-generation microbiome solution. The resulting formulation is based on Bereum’s flagship strain, heat-inactivated Lactobacillus plantarum beLP1, which underpins the development of Atomy Postbiotics Core Balancer 5000.
Clinical evaluation
Clinical evaluation of heat-inactivated Lactobacillus plantarum beLP1 has indicated its potential role in modulating gut microbiota composition, including increases in beneficial bacterial populations and suppression of opportunistic strains. In a recent human study evaluating gut health parameters, supplementation with the strain was associated with improvements in gut comfort, alongside a positive trend in inflammatory biomarker TNF-α levels compared to placebo.
Together, these findings suggest its potential to support microbiome balance and host immune response through microbial cell-mediated interactions.
Industry collaboration and commercial expansion
Building on its established microbiome product portfolio across multiple international markets including South Korea, the US, Europe, Russia, China, Japan, Taiwan, Malaysia, and Singapore, Atomy is now entering the postbiotics category with a high-density formulation aimed at elevating its microbiome strategy.
The move reflects a broader plan to diversify its biotics portfolio at a time when global consumers are increasingly seeking stable, science-driven, next-generation microbiome solutions.
Over the past three years, Bereum and Atomy have worked closely on joint clinical research and formulation development to translate scientific findings into a commercially viable high-density postbiotic product. The resulting formulation is based on Bereum’s flagship strain, heat-inactivated Lactobacillus plantarum beLP1, which underpins the development of Atomy Postbiotics Core Balance 5000.
“With Atomy Postbiotics Core Balance 5000, our priority was to deliver a high-density formulation that provides meaningful microbiome support in a simple, convenient format,” says Dr. Im-Joung La, head of R&D center at Atomy.
“As interest in postbiotics continues to grow, we believe this category offers a unique combination of stability, potency, and scientific clarity that can broaden how consumers approach gut and immune health.”
Atomy debuted Postbiotics Core Balance 5000 in South Korea in late February and is preparing for launches in at least four additional global markets this year.
